Umeå universitet

Expanded Understanding Of Promising Blood Fat-Lowering Protein

Article
Vein & Vascular Health
Behavioral & Mental Health
+4
Contributed byMaulik P. Purohit MD MPHFeb 18, 2016

New research on the blood lipid-lowering protein FGF21 shows how it redistributes fatty acids by two distinct mechanisms. The discovery could lead to improved pharmaceutical treatment for type 2 diabetes and other obesity-related diseases. This according to a new study published in the journalCell Metabolism.

"The protein FGF21 is an exciting potential therapeutic agent for the treatment of cardiovascular diseases and type 2 diabetes. This study provides breakthrough understanding mode of action of the protein," says Stefan K. Nilsson, assistant professor at the Department of Medical Biosciences at Umeå University, who took part in the study as visiting scientist at the University Medical Centre in Hamburg.

The research results, published in the journal Cell Metabolism, shows that a part of FGF21's redistributing effect on fatty acids can be explained by the fat-splitting enzyme Lipoprotein lipase (LPL).

"LPLs have been of interest to researchers at Umeå University for 50 years, which makes it especially rewarding to have contributed to this study," says Stefan K. Nilsson.

The study was conducted at the University Medical Center in Hamburg in collaboration with the pharmaceutical company Pfizer. The hope is that this research will lead to new therapeutic agents in the future. A drug that stimulates this pathway could be used to treat and reduce clinical manifestations of obesity-related health problems such as cardiovascular disease and type 2 diabetes.

"My visiting research fellowship in Hamburg is merely the start of a continuous collaboration with one of the strongest research teams in the area of cellular fat transport. This will, of course, be beneficial to future studies on blood lipids here at Umeå University," continues Stefan K. Nilsson.

The researchers have studied what mechanisms are responsible for the protein FGF21's reducing of blood lipid levels. The results show that FGF21 lowers the release of free fatty acids from the white adipose tissue, this decreases the release of liver produced blood lipids. The reduced levels of blood lipids are also due to the fact that FGF21 activate the enzyme Lipoprotein lipase, which is active mainly in the adipose and muscle tissue of the body. Elevated enzyme activity leads to faster hydrolytic cleavage and uptake of blood lipids.

In the study, the researchers also found that FGF21 changed the metabolic pattern in diabetic mice models and increased their metabolism of excess energy via brown adipose tissue.


The above post is reprinted from materials provided by Umeå universitet.Note: Materials may be edited for content and length.

Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

Schlein, C., Talukdar, S., Heine, M., Fischer, A. W., Krott, L. M., Nilsson, S. K., ... & Scheja, L. (2016). FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues.Cell Metabolism.

Was this article helpful

On the Article

Maulik P. Purohit MD MPH picture
Approved by

Maulik P. Purohit MD MPH

Assistant Medical Director, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!